ClinicalTrials.gg
RecruitingNCT06805552Sarco HCCUpdated Feb 3, 2025

Sarcopenia and Systemic Therapy in HCC

An observational study in HCC - Hepatocellular Carcinoma, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
270
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Carcinoma, Hepatocellular by IRCCS Azienda Ospedaliero-Universitaria di Bologna — 9 open to participants now, 9 under way, none of them phase 3. Carcinoma, Hepatocellular · IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Planned enrollment
6th of 11
270 · median 270
Started
2022
with 3 others
Observational
11 of 13
9 open now
Registered
11th of 13
by date

Among the 13 studies in Carcinoma, Hepatocellular by IRCCS Azienda Ospedaliero-Universitaria di Bologna, this one is the 6th largest by planned enrollment of the 11 observational ones that give a count, is one of 4 that started in 2022, is one of 11 observational ones, and was the 11th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

9 of the 13 studies in Carcinoma, Hepatocellular by IRCCS Azienda Ospedaliero-Universitaria di Bologna are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Carcinoma, Hepatocellular by IRCCS Azienda Ospedaliero-Universitaria di Bologna, or all of them as a file.
02

Study summary

This is a multi-center, retrospective observational study in patients with liver cancer (HCC) to assess the impact of sarcopenia (muscle loss) on the prognosis, duration, and tolerance of systemic treatment.

Read the detailed description

The impact of sarcopenia will be assessed 12 months after the start of chemotherapy. Additionally, other factors affecting prognosis will be investigated to develop a specific predictive model for the risk of death at 12 months. Finally, an external validation of this predictive model for the risk of death will be carried out.

03

Conditions studied

  • HCC - Hepatocellular Carcinoma

Keywords

  • Hepatocellular Carcinoma
  • Sarcopenia
  • HCC systemic therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients affected with Hepatocellular Carcinoma

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged ≥18 years.
  • Diagnosis of hepatocellular carcinoma based on histological and/or radiological results as defined by the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD). The staging of hepatocellular carcinoma was obtained through contrast-enhanced liver CT and/or MRI.
  • Patients with advanced (BCLC-C) or intermediate (BCLC-B) stage hepatocellular carcinoma, or patients with early-stage (BCLC-A) hepatocellular carcinoma who have not responded to previous locoregional ablative treatments and/or liver resection.
  • Treatment with TKIs according to the indications and prescription criteria defined by AIFA, with no requirement to reach a minimum treatment period.

Availability of a CT scan performed within no more than 8 weeks prior to the start of TKI therapy.

  • Obtaining written .

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
270 participants (estimated)
Patient registry
No

Groups and cohorts

  • HCC Patients

    Patients with hepatocellular carcinoma treated with systemic therapy

06

What researchers measure

Primary outcomes

  1. Prognostic role of Sarcopenia in HCC patient's survival

    Evaluation of the prognostic role of sarcopenia in the survival of patients affected by HCC in liver cirrhosis and candidates for systemic treatment. Possible development of a specific classification system for the risk of death.

    Time frame: From January 2008 to April 2021

Secondary outcomes

  1. Role of Sarcopenia in HCC systemic therapy tolerability

    Evaluation of the role of sarcopenia on the duration and tolerability of systemic treatment in patients affected by HCC in liver cirrhosis.

    Time frame: From January 2008 to April 2021

07

Study locations

1 of 1 sites recruiting
  • IRCCS AOUBO Policlinico di S.Orsola
    Bologna, 40138, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Nov 2025, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2025
First posted
Feb 3, 2025
StartActual
Oct 19, 2022
Primary completionEst.
Nov 1, 2025
CompletionEst.
Nov 1, 2025
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06805552
Responsible party
Sponsor
First posted
Feb 3, 2025
Start date
Oct 19, 2022
Primary completion
Nov 1, 2025 (estimated)
Completion
Nov 1, 2025 (estimated)
Last update
Feb 3, 2025

Study contacts

Dr. Maurizio Biselli Principal Investigator, MD
Contact
maurizio.biselli@unibo.it
+39 051 2142928

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion